Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia

BMC Urology

Research

Marniza Saad¹  Jasmine Lim²  Teng Aik Ong²  Hsien Hooi Lee³ 

[1] Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;Johnson & Johnson Pte. Ltd., Petaling Jaya, Selangor, Malaysia;

关键词: Advanced prostate cancer;    Southeast Asia;    New generation androgen receptor-axis targeted therapies;    Abiraterone acetate;    Enzalutamide;    Apalutamide;    Darolutamide;   

DOI  :  10.1186/s12894-022-01156-8

 received in 2022-09-16, accepted in 2022-12-02,  发布年份 2022

来源: Springer

【 摘 要 】

There is a paucity of information on the use of novel hormonal agents in Southeast Asian patients. We reviewed the clinical roles of novel hormonal therapy (NHT), namely abiraterone acetate (AA), enzalutamide, apalutamide and darolutamide, in the management of advanced prostate cancer, and data on its use in Asian patients, in order to extrapolate these findings to the Southeast Asian patient population. There are some differences in the molecular features between the NHTs, which influenced their respective permeabilities through the blood–brain barrier. The Asian sub-analyses of the landmark studies of each NHT were limited. The primary endpoints of the Asian sub-analyses generally reflect the efficacy outcomes of the respective landmark study. Hypertension, fatigue, musculoskeletal disorders, rash, and hot flushes were among the common toxicities observed in Asian patients. Real-world data on AA in the Asian setting is favourable, but data is limited for enzalutamide, apalutamide and darolutamide. Based on the sub-analyses and real-world data, the efficacy and safety of NHTs in the Asian patients showed a similar trend to the respective landmark studies. The lack of clinical trials in the Southeast Asian region hampers the ability to make a robust conclusion on any specific efficacy or safety differences that may be present; clinicians must assume that the broader Asian sub-analyses and real-world data reflects Southeast Asian patients' outcomes.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

40249_2022_1049_Article_IEq52.gif

42004_2022_803_Article_IEq37.gif

Scheme 1

12894_2022_1156_Figa_HTML.png